摘要
目的分析鲍曼不动杆菌和铜绿假单胞菌耐药性变迁,以期指导临床抗菌药物的合理应用。方法分析平顶山市第五人民医院2017-01-01-2019-12-31收治的3176例住院患者送检呼吸道黏液、血液、中段尿等各类标本的临床资料,统计鲍曼不动杆菌和铜绿假单胞菌的耐药性变迁情况。结果2019年鲍曼不动杆菌的检出率高于2018和2017年,2017-2019年鲍曼不动杆菌检出率呈上升趋势,差异有统计学意义,P<0.05;2019年铜绿假单胞菌的检出率低于2018年和2017年,2017-2019年铜绿假单胞菌检出率呈下降趋势,差异有统计学意义,P<0.05;2017-2019年鲍曼不动杆菌对头孢吡肟耐药性变迁情况比较,差异无统计学意义,P>0.05;2019年鲍曼不动杆菌对阿米卡星、环丙沙星、哌拉西林/他唑巴坦、左氧氟沙星和亚胺培南的耐药性变迁情况高于2018和2017年,对头孢他啶的耐药性低于2018和2017年,差异有统计学意义,P<0.05;2017-2019年铜绿假单胞菌对阿米卡星、头孢他啶、左氧氟沙星和头孢吡肟的耐药性变迁情况比较,差异无统计学意义,P>0.05;2019年铜绿假单胞菌对哌拉西林/他唑巴坦的耐药性变迁情况高于2017和2018年,对亚胺培南、氨曲南和环丙沙星的耐药性变迁情况低于2017和2018年,差异有统计学意义,P<0.05。结论2017-2019年鲍曼不动杆菌和铜绿假单胞菌对临床常用抗菌药物均呈现高度耐药,且耐药性变迁情况逐渐增加,临床上应合理应用抗菌药物,以降低鲍曼不动杆菌和铜绿假单胞菌耐药性。
Objective To analyze the changes in drug resistance of Acinetobacter baumannii and Pseudomonas aeruginosain order to guide the rational application of clinical antibacterial drugs.Methods The clinical data of various specimens including respiratory mucus,blood,and mid-stage urine of 3176 hospitalized patients in Pingdingshan Fifth People’s Hospital from January 1,2017 to December 31,2019 were retrospectively analyzed,the changes in drug resistance of Acinetobacter baumannii and Pseudomonas aeruginosa and their correlation with the dosage of antibacterial drugs were counted.Results The detection rate of Acinetobacter baumannii in 2019 was higher than that in 2018 and 2017,and the detection rate of Acinetobacter baumannii showed an upward trend from 2017 to 2019,and the difference was statistically significant(P<0.05);the detection rate of Pseudomonas aeruginosain 2019 was lower than that in 2018 and 2017.The detection rate of Pseudomonas aeruginosa from 2017 to 2019 showed a downward trend,and the difference was statistically significant(P<0.05);compared the changes in the resistance of Acinetobacter baumannii to cefepime in 2017,2018,and2019,there was no statistically significant difference(P>0.05);the resistance of Acinetobacter baumannii to amikacin,ciprofloxacin,piperacillin/tazobactam,levofloxacin,and imipenem in 2019 was higher than that in 2018 and 2017.The resistance to ceftazidime was lower than that in 2018 and 2017,and the difference was statistically significant(P<0.05);compared the resistance changes of Pseudomonas aeruginosa to amikacin,ceftazidime,levofloxacin,and cefepime in2017,2018,and 2019,the difference was not statistically significant(P>0.05);the resistance of Pseudomonas aeruginosa to piperacillin/tazobactam in 2019 was higher than that in 2017 and 2018.The changes in resistance to imipenem,aztreonam,and ciprofloxacin were lower than in 2017 and 2018,and the difference was statistically significant(P<0.05).Conclusions In 2017-2019,Acinetobacter baumannii and Pseudomonas aeruginosa were highly resistant to clinically commonly used antibacterial drugs,and the changes in resistance were gradually increasing.Clinically,antibiotics should be used rationally to reduce the drug resistance of Acinetobacter baumannii and Pseudomonas aeruginosa.
作者
刘桂琴
蒋翠霞
LIU Gui-qin;JIANG Cui-xia(Department of Laboratory Medicine,Pingdingshan Fifth People's Hospital,Pingdingshan 467300,China;Department of Laboratory Medicine,Zhengzhou Seventh People's Hospital,Zhengzhou 450000,China)
出处
《社区医学杂志》
CAS
2021年第13期807-810,共4页
Journal Of Community Medicine
基金
江门市科技攻关项目(2019A079)
关键词
鲍曼不动杆菌
铜绿假单胞菌
耐药性变迁
抗菌药物用量
相关性
Acinetobacter baumannii
Pseudomonas aeruginosa
changes of drug resistance
dosage of antibacterial drugs
correlation
作者简介
通信作者:刘桂琴,女,河南平顶山人,主管检验师,主要从事免疫微生物学的研究工作。E-mail:yelairedwr9@163.com
